# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
ABVC BioPharma (NASDAQ:ABVC) reported quarterly losses of $(0.13) per share. This is a 44.44 percent decrease over losses of $(...
ABVC BioPharma, Inc. (NASDAQ:ABVC), a clinical-stage biopharmaceutical company developing botanical-based therapies for central...
- SEC Filing
- SEC Filing
ABVC BioPharma, Inc. (NASDAQ:ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmolog...